Xeljanz Lawsuit: Where the Cases Stand in 2026
Questions about this case?
AI Legal Assistant · free · answers in seconds · general information, not legal advice
As of October 5, 2026, there is no Xeljanz settlement, no class action and no claim form. What exists are individual lawsuits by patients who allege that Pfizer did not adequately warn about blood clots, heart problems and cancer — the risks the FDA added to the drug’s Boxed Warning in 2021. Xeljanz is back in the news for a different reason: on June 3, 2026, Aurobindo announced FDA approval of generic tofacitinib tablets and Hikma announced a U.S. launch of a generic oral solution.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the Lawsuits Say
Xeljanz (tofacitinib) is Pfizer’s pill for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. On September 1, 2021 the FDA concluded, from a large randomized safety trial, that there is “an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death” with Xeljanz and Xeljanz XR. It required revisions to the Boxed Warning, its most prominent warning, and limited approved uses to patients who have not responded to or cannot tolerate one or more TNF blockers.
The lawsuits allege that Pfizer did not adequately warn doctors and patients about those risks. According to Drugwatch, a site run by a plaintiffs’ firm, the suits filed so far are individual cases by patients who suffered blood clots, cardiovascular problems or cancer after taking the drug. These are allegations; Pfizer has not been found liable, and Xeljanz has not been recalled.
Two other legal tracks share the name but do not involve patients: Pfizer’s own patent suits against generic makers, and a Justice Department inquiry into pharmacy programs (both below).
Case Details
Injury cases. We found no multidistrict litigation (MDL) and no class action for Xeljanz injuries. Each case is filed by one patient in a state or federal court and moves on its own schedule; we could not confirm a lead docket number.
Patent cases (Pfizer as plaintiff). Beginning in 2017, Pfizer sued generic manufacturers that sought FDA approval for tofacitinib, with the remaining actions pending, as of Pfizer’s 2024 filing, in the U.S. District Court for the District of Delaware. These are business disputes; patients get nothing from them.
Government inquiry. In April 2023 Pfizer received a HIPAA subpoena from the U.S. Attorney’s Office for the Western District of Virginia, working with the Justice Department’s Commercial Litigation Branch, seeking records on “programs Pfizer sponsored in retail pharmacies relating to Xeljanz.” Pfizer reported that it produced the records. The inquiry was still listed in its annual report filed February 26, 2026, but not in its quarterly report filed August 4, 2026. Pfizer has not said publicly why, and no settlement has been announced.
Status: Individual Cases, No Settlement
The June 2026 news is commercial, not legal: on June 3, 2026 Aurobindo announced FDA approval of generic tofacitinib tablets, and Hikma announced a U.S. launch of generic tofacitinib oral solution. Generics carry the same Boxed Warning as the brand, and their arrival does not create or end any lawsuit.
Who Can Bring a Xeljanz Lawsuit
There is no class to join. A claim is personal: someone who took Xeljanz or Xeljanz XR and then had a blood clot (such as a pulmonary embolism or deep vein thrombosis), a heart attack, a stroke or a cancer such as lymphoma or lung cancer, or a family member after a death. Lawyers look at when you took the drug, which dose, your medical records, and your other risk factors — the FDA itself names smoking and prior heart problems as factors that raise the risk.
Timing matters more than anything else. Every state has a filing deadline for injury claims, usually counted from when you knew or should have known about the injury and its possible cause. The FDA’s public warnings date to 2019 and 2021, which a defense lawyer may argue started the clock. Check our statute of limitations by state and talk to a lawyer before assuming you are still in time.
What a Xeljanz Lawsuit Could Pay
In individual drug cases, value tracks the injury: documented medical bills, lost income, the severity and permanence of the harm, and how strong the evidence is that the drug, rather than other risk factors, caused it. Many such cases end with a confidential settlement or no payment at all. Our personal injury value guide explains the components.
Xeljanz Safety and Legal Timeline
- 1
2012 — FDA Approval
Xeljanz becomes the first drug of its class (JAK inhibitors) approved in the U.S., initially for rheumatoid arthritis.
- 2
February and July 2019 — First Safety Signals
The FDA communicates about an ongoing safety trial comparing Xeljanz with TNF blockers. Individual lawsuits follow, including one filed in July 2019 alleging failure to warn.
- 3
September 1, 2021 — Boxed Warning Expanded
After the trial’s final results, the FDA requires warnings about heart attack, stroke, cancer, blood clots and death, and restricts use to patients after TNF blockers. Labels are updated in December 2021.
- 4
April 2023 — Justice Department Subpoena
Pfizer receives a HIPAA subpoena from the U.S. Attorney’s Office for the Western District of Virginia about retail-pharmacy programs relating to Xeljanz.
- 5
June 3, 2026 — Generic Tofacitinib
Aurobindo announces FDA approval of generic tofacitinib tablets; Hikma announces a U.S. launch of a generic oral solution.
- 6
October 2026 — Individual Cases, No Settlement
As of October 5, 2026, injury claims proceed one by one. No MDL, no class action, no Xeljanz settlement and no claim form exist.
Three Things to Watch For
A well-known drug with a Boxed Warning and no claims process attracts lead-generation schemes:
“Xeljanz settlement payout” letters or texts
There is no Xeljanz settlement fund and no administrator. A message saying you are “owed” money, or asking for your bank details or a processing fee to release it, is not real.
“Join the Xeljanz class action” forms
No Xeljanz class action exists. Ad-driven “eligibility quizzes” mostly collect your diagnosis and contact details to sell to firms. If you want a lawyer, choose one yourself and read the retainer before signing.
Calls about switching to generic
The 2026 generic launch gives callers an easy script. Your pharmacy or doctor handles a switch to tofacitinib; nobody legitimate calls to ask for your insurance ID or Social Security number to “update your lawsuit file.”
Xeljanz Lawsuit — Questions People Actually Ask
Is there a Xeljanz class action lawsuit?
No. As of October 5, 2026, we found no Xeljanz class action and no multidistrict litigation. The lawsuits are individual injury cases, each filed by one patient or family.
Is there a Xeljanz settlement I can claim from?
No. There is no Xeljanz settlement, no fund, no claim form and no deadline. If a group settlement is ever announced, it would run through the lawyers of people who already filed suit, not through a public website.
What injuries are the lawsuits about?
Blood clots such as pulmonary embolism and deep vein thrombosis, heart attacks and strokes, cancers including lymphoma and lung cancer, and deaths — the risks the FDA added to the Boxed Warning in 2021. The suits allege Pfizer did not warn adequately; Pfizer has not been found liable.
Was Xeljanz recalled?
No. Xeljanz remains on the market with a Boxed Warning, and since 2021 its approved uses are limited to patients who have not responded to or cannot tolerate one or more TNF blockers. Do not stop the drug on your own; talk to your doctor.
Does generic tofacitinib change anything?
Not for lawsuits. Generic tofacitinib announced on June 3, 2026 carries the same warnings. Claims against generic makers over warning labels are generally much harder to bring than claims against the brand company, which is a question for a lawyer if you took only the generic.
What was the Justice Department looking into?
Pfizer disclosed an April 2023 subpoena seeking records on programs it sponsored in retail pharmacies relating to Xeljanz. That inquiry concerns government health programs, not patient compensation, and Pfizer’s August 2026 quarterly report no longer lists it.
Is it too late to file a Xeljanz lawsuit?
It may be. Filing deadlines vary by state and often run from when you learned of the injury and its possible link to the drug. The FDA warnings date to 2019 and 2021. A lawyer in your state can tell you whether a deadline has passed.
What should I do if I took Xeljanz and got sick?
Keep your pharmacy records showing the dose and dates, and request medical records for the diagnosis. Write down when you first connected the illness to the drug. Then speak to a licensed attorney — there is nothing to sign up for and no claim form to file.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.
Related Consumer Brand Lawsuits
Pfizer Lawsuit Tracker
Depo-Provera, Chantix, Zantac and other Pfizer cases, one by one
Open Class Action Settlements
Settlements that are taking claims right now, with deadlines
Personal Injury Case Value
How injury claims are valued: medical costs, lost wages, severity
Statute of Limitations by State
Filing deadlines for injury claims, state by state